Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Alzheimer's, Cassava
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Key Takeaways Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC.The SEC said that Cassava made misleading statements about a clinical trial of its Alzheimer’s disease drug.
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
After $40M settlement, Alzheimer's drug under scrutiny as human trials proceed
The scrutiny follows allegations of data manipulation and misleading claims about the drug's effectiveness, leading the Securities and Exchange Commission to charge the company, which resulted in a $40 million settlement.
Alzheimer’s Drug Developer Cassava Paying $40 Million to Settle Doctored Data Claims
The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug results look more promising.
Cassava Sciences settles with SEC for $40M over skewed Alzheimer’s drug data
A former Alzheimer's researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its former chief executive reaching a $40 million settlement with the Securities and Exchange Commission over allegedly misleading the public.
STAT
1d
After Cassava Alzheimer’s drug fiasco, the FDA must intervene to protect patients
The SEC concluded that Cassava Sciences falsified data in its Alzheimer’s clinical trials. Now the FDA needs to act, ...
bovnews
5h
Cassava Sciences Inc (SAVA) Stock: Analyzing Its Quiet Power
In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...
1d
Cassava's Alzheimer's Therapy: A Confidence Bet
The SEC has fined Cassava Sciences $40 million for misleading investors on the company's Alzheimer's drug candidate simufilam ...
STAT
1d
Lilly invests $4.5 billion in a new research hub
Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...
5d
Why Cassava Sciences Stock Dived by Almost 11% Today
Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...
FierceBiotech
6d
Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
8d
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
6d
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
JD Supra
2d
SEC brings securities fraud charges against Cassava Sciences
The SEC announced last week that it had filed a complaint against Cassava Sciences, Inc., a “pharmaceutical company with one primary drug ...
6d
on MSN
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Alzheimer's disease
U.S. Securities and Exchange Commission
Feedback